Command Palette

Search for a command to run...

BALPHARMA

82.61-0.59%
Market Cap
₹132.92 Cr
Stock P/E
18.57
ROCE
10.10%
ROE
9.69%
Book Value
₹48.75

Financials

YoY Net Sales
EPS Growth
Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings
Distribution
Promoter
Public
Others

From Last Concall

No Concall Summary

Conference call summary is not available for this stock.

Peers Summary

Sector Leader

Bal Pharma Ltd. demonstrates moderate growth and reasonable valuation metrics compared to its peers in the Pharmaceuticals & Drugs sector. While it shows potential in profitability, there are stronger performers in terms of growth and returns on equity. Companies like Dr. Reddy's Laboratories and Cipla are leading in profitability, while Bal Pharma is relatively stable but lacks exceptional metrics. However, it remains a viable option for investors seeking value in a competitive landscape.

Key Points
  • Bal Pharma shows a solid revenue growth of 11.51% YoY, but peers like Mankind Pharma lead with 18.12%.
  • The company's PE ratio at 18.10 positions it favorably compared to many peers, indicating potential value.
  • ROE of 11.19% is lower than top performers like Dr. Reddy's (21.76%), suggesting room for improvement in shareholder returns.
Top Performers
Dr. Reddy's Laboratories Ltd.

Highest ROE of 21.76% and strong growth metrics.

Cipla Ltd.

High profitability with an ROE of 16.63% and a decent growth rate.

Mankind Pharma Ltd.

Best revenue growth at 18.12% YoY, indicating strong market performance.

Leveling the playing field in markets.

© 2025 EQHQ Technologies Pvt Ltd

"Information provided is for educational purposes only and not financial advice.